Stroma

Patel, Rikesh; Filer, Andrew; Barone, Francesca; Buckley, Christopher D.

DOI:

[10.1016/j.berh.2014.10.022](https://doi.org/10.1016/j.berh.2014.10.022)

License:

Other (please specify with Rights Statement)

Document Version

Peer reviewed version

Citation for published version (Harvard):

Patel, R, Filer, A, Barone, F & Buckley, CD 2014, 'Stroma: fertile soil for inflammation', *Best Practice & Research: Clinical Rheumatology*, vol. 28, no. 4, pp. 565-576. <https://doi.org/10.1016/j.berh.2014.10.022>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

NOTICE: this is the author's version of a work that was accepted for publication. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published as Patel R, Filer A, Barone F, Buckley CD, Stroma: Fertile soil for inflammation, *Best Practice & Research Clinical Rheumatology* (2014), doi: 10.1016/j.berh.2014.10.022.

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Accepted Manuscript

Stroma: Fertile soil for inflammation

Rikesh Patel, Andrew Filer, Francesca Barone, Christopher D. Buckley

PII: S1521-6942(14)00104-1

DOI: [10.1016/j.berh.2014.10.022](https://doi.org/10.1016/j.berh.2014.10.022)

Reference: YBERH 1106

To appear in: *Best Practice & Research Clinical Rheumatology*

Please cite this article as: Patel R, Filer A, Barone F, Buckley CD, Stroma: Fertile soil for inflammation, *Best Practice & Research Clinical Rheumatology* (2014), doi: 10.1016/j.berh.2014.10.022.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Stroma: Fertile soil for inflammation

Rikesh Patel,
Andrew Filer,
Francesca Barone,
Christopher D. Buckley

Rheumatology Research Group, Center for Translational Inflammation Research,
University of Birmingham, Edgbaston, Birmingham, B15 2TT UK.

Correspondence: Christopher Buckley, Centre for Translational Inflammation Research, University of Birmingham, Edgbaston, Birmingham, B15 2TT. Telephone: +44 (0)121 371 3240. Email: c.d.buckley@bham.ac.uk

Keywords

Inflammation, fibroblast, stroma, stromal cell, rheumatoid arthritis, synovium

Contents

Abstract	Error! Bookmark not defined.
1.0 Introduction	Error! Bookmark not defined.
2.0 The stroma	Error! Bookmark not defined.
2.1 Fibroblast biology	Error! Bookmark not defined.
2.2 Pathogenic Stroma	Error! Bookmark not defined.
2.3 Acute inflammation	Error! Bookmark not defined.
2.4 The recruitment postcode	Error! Bookmark not defined.
2.5 Fibroblast activation	Error! Bookmark not defined.
3.0 The stroma in chronic inflammation	Error! Bookmark not defined.
3.1 Accumulation of epigenetic changes and stability of the inflamed microenvironment	Error! Bookmark not defined.
3.2 Recruitment of leukocytes to sites of chronic inflammation	Error! Bookmark not defined.
3.3 Retention of lymphocytes	7
3.4 Tertiary lymphoid organs (TLOs)	Error! Bookmark not defined.
3.5 Inhibition of leukocyte apoptosis	Error! Bookmark not defined.
3.6 Tissue destruction in RA	Error! Bookmark not defined.
3.7 p21 cyclin dependent kinase inhibitors (CDKi)	8
3.8 The synovium in patients with early rheumatoid arthritis	9
4.0 Biological agents in RA that target the stroma	9
4.1 Possible future stromal targets	10
5.0 Conclusions	10
6.0 Practice points	11
7.0 Research Agenda	11

Abstract

Biological therapies for the management of immune mediated inflammatory diseases such as rheumatoid arthritis have proven to be extremely successful in recent years. Despite these successes, even the most effective of therapies do not lead to cure. Why chronic inflammation persists indefinitely within the rheumatoid synovium despite an absence of continuous stimulation, and why some patients with early synovitis progress to persistent disease whilst others do not, has remained unexplained. In contrast to the paradigm that stromal cells are biochemically active but immunologically passive, there is now growing evidence that stromal components from the rheumatoid synovium play a crucial part in the immunopathology of rheumatoid arthritis. Stromal cells play a central role in the transformation of an acute, resolving to a chronic inflammatory process, and to the persistence of synovial inflammation and joint destruction through a variety of immune mechanisms. Therapeutic manipulation of the stroma is a largely unexplored, yet potentially vital area of research. Targeting pathogenic stromal cells has the potential to provide a cure for chronic inflammatory disorders such as rheumatoid arthritis.

1.0 Introduction

Inflammation is an intrinsic, biological response that occurs to protect organisms against harmful stimuli. At a cellular level, inflammation is characterised by an influx of leukocytes into damaged or infected tissue. The duration, type and magnitude of leukocyte influx is controlled by cytokine and chemokine gradients. For an inflammatory response to resolve completely, these gradients must be removed, and leukocytes must be cleared from the site of pathology, either by migration out of the site, or via apoptosis (1).

Episodes of acute inflammation most often occur in the context of infection; these episodes are transient, often self-limiting and are followed by a phase of tissue repair leading to health. Chronic, persistent inflammation in contrast often occurs in the absence of a pathogen, and in the case of autoimmune diseases such as rheumatoid arthritis, may persist indefinitely even in the absence of a harmful external stimuli.

The current and established pharmacological management of most autoimmune pathologies aims to dampen the persistent, harmful inflammatory response in the tissue affected. This approach of minimising damage and progression of disease is however suboptimal. The optimal approach is to reverse the fundamental pathological process.

Our understanding of the role that stromal cells play in inflammation has changed considerably. Stromal cells, in particular fibroblasts, are emerging as key drivers in the genesis of tissue specific inflammation, modulation of tissue microenvironments, transformation from acute to chronic inflammation and persistence of inflammation through a multitude of immune-mediated modalities, particularly in rheumatoid arthritis (2). These discoveries raise the possibility that stromal cells may turn out to be novel therapeutic targets in the discovery of a cure for chronic inflammatory diseases.

This review aims to highlight the role that fibroblasts, a key cellular component of the stroma, play in the genesis and persistence of chronic inflammation in rheumatoid arthritis and to provide an insight into how currently available biologic agents modulate stromal cell function. It will also outline possibilities for novel stromal cell targets, which may be beneficial in future therapies for rheumatoid arthritis.

2.0 The stroma

Tissue stroma comprises the subendothelial basement membrane and the underlying connective tissue containing stromal cells such as pericytes, fibroblasts and organ specific stromal cells (astrocytes, hepatocytes) and epithelial cells as well as adipocytes (2). The extracellular matrix that lies between stromal cells is comprised mainly of glycosaminoglycans and proteoglycans. Lymphatic and blood vessels and nervous tissue is interspersed throughout the stroma. It is through this matrix that leukocytes migrate to and from an area of inflammation (3). Considerable effort has been expended in targeting vascular endothelial cells in cancer and inflammation. While new anti-angiogenic agents have shown promise in some cancers, their application to autoimmune diseases remain disappointing.

2.1 Fibroblast biology

The fibroblast is the most common cell type within the stroma (4). Fibroblasts are identified by their spindle-shape morphology, expression of interstitial collagens (types I and III) and their adherence to plastic in culture (5). Fibroblasts express numerous markers which aid in their identification (6) (Table 1). However None of these markers is highly specific to fibroblasts, nor is any marker reliably present in all fibroblasts (7). Because of this, there has been until recently a lack of information on the origin, function and role of fibroblasts in disease (8).

Mesenchymal Stromal cells (MSCs) are multipotent cells, which are currently undergoing extensive investigation for use in tissue repair. They share common cell surface markers, morphology and immunologic properties with fibroblasts (9). It is currently, although not exclusively accepted,

that MSCs and fibroblasts are distinct cell types, set apart by the ability of MSCs to differentiate into any mesodermal tissue (10) and the discovery that fibroblasts are not always mesodermal in origin. For example fibroblasts in the head and neck arise from the ectoderm through a process termed epithelial to mesenchymal transition (EMT) (11).

Under physiological conditions, the stroma functions primarily to provide structure by synthesising and remodelling the extracellular matrix (ECM). Fibroblasts synthesise type I, type III and type V collagen, and fibronectin (12) but also have a role ECM degradation via matrix metalloproteinases (MMPs) (13). Thus fibroblasts have prime responsibility for the maintenance of ECM homeostasis by regulating matrix turnover (7). Fibroblasts also help in maintaining biochemical homeostasis between adjacent epithelial cells (7) and have a key role in tissue development, differentiation and repair (including fibrosis) (14).

Of the cells that comprise the stroma, the fibroblast has been most implicated in generating and directing both the innate and adaptive immune response in health and disease (14). Synovial fibroblasts from patients with rheumatoid arthritis have provided key information on how the stroma is responsible for persistence of chronic inflammation. This is discussed in detail below.

Table 1: Fibroblast markers

Marker	Function	Fibroblast subtype	Expressed elsewhere
Vimentin	Intermediate filament associated protein	Miscellaneous	Endothelial cells, myoepithelial cells, neurons
α -SMA	Intermediate filament associated protein	Myofibroblasts	Vascular smooth muscle cells, pericytes, myoepithelial cells
Desmin	Intermediate filament associated protein	Skin fibroblasts	Muscle cells, vascular smooth muscle cells
FSP1	Intermediate filament associated protein	Miscellaneous	Invasive carcinoma cells
Discoidin-domain receptor 2	Collagen receptor	Cardiac fibroblasts	Endothelial cells
FAP*	Serine protease	Activated fibroblasts	Activated melanocytes
α 1 β 1 integrin	Collagen receptor	Miscellaneous	Monocytes, endothelial cells
Prolyl 4-hydroxylase	Collagen biosynthesis	Miscellaneous	Endothelial cells, cancer cells, epithelial cells
Pro-collagen1 α 2	Collagen-1 biosynthesis	Miscellaneous	Osteoblasts, chondroblasts
CD248*	Unknown	Miscellaneous	Pericytes
VCAM-1	Cell adhesion	Miscellaneous	Activated endothelial cells
gp38*	Invasiveness in cancer	Miscellaneous	Alveolar cells, podocytes, endothelial cells, neurons
Cadherin-11*	Homotypic adhesion	Miscellaneous	Nil

Adapted from Kalluri and Zeisberg (2006) (7) and Filer (2013) (15) *of particular significance as a possible therapeutic target

2.2 Pathogenic Stroma

Stromal tissue has been shown to play a functional role in three chronic pathological states: malignant disease, tissue fibrosis and chronic inflammation (16). In all of these conditions, stromal cells have been observed to undergo specific, disease dependent phenotypic and functional changes which promote the disease state (17). In malignancy for example, in addition to production of the

non-tumour extracellular matrix that facilitates growth of solid tumours, the stroma has been shown to be a key driver of tumour progression by inhibiting apoptosis of malignant cells in breast carcinoma (18). Fibroblast activation protein (FAP), a serine protease that is selectively expressed in reactive fibroblasts of epithelial cancers has also been noted to have a pathogenic role in malignancy (19). FAP blockade in mice models of pancreatic ductal carcinoma has been shown to induce hypoxic necrosis of tumour and stromal cells in a process that is dependent on Interferon gamma (IFN γ) and TNF alpha (TNF α) (20). In addition to these effects, reactive stroma and cancer associated fibroblasts are also known to facilitate tumourigenesis and metastasis via generation of oncogenic signals (21) and promotion of angiogenesis (22).

2.3 Acute inflammation

During episodes of acute inflammation, vascular endothelial cells (ECs) are responsible for the immediate recruitment of specific leucocyte subsets to an area of acute pathology by expressing specific adhesion molecules and chemokines in response to biochemical signals generated by inflammatory/infectious/traumatic tissue injury (23-25). In the acute inflammatory response to infection, tissue resident macrophages may release cytokines such as IL-1 or TNF α . Along with bacterial components, and activated complement fragments, these cytokines stimulate vascular ECs to express adhesion molecules that interact with surface presented chemokines or other mediators, that, in turn, activate leukocyte integrins (2). The types and patterns of adhesion receptors expressed as well as the chemokine gradients are determined by the nature of the stimulus driving the inflammatory response (26-30). For example, $\alpha_M\beta_2$ -integrin binds intracellular adhesion molecule 1 (ICAM-1) to stabilize adhesion and supports migration of neutrophils to the site of acute inflammation (2). Capturing peripheral blood leukocytes (PBLs) to an area of chronic inflammation in contrast, requires $\alpha_4\beta_1$ -integrin to bind to vascular cell adhesion molecule 1 (VCAM-1), a process which is stabilised by the chemokine CXCR3 (27).

Whilst the EC is the principal cell type controlling leukocyte migration into an area of acute inflammation, stromal components are known to have an important role in the regulation of this response. When co-cultured ECs and fibroblasts are exposed to the pro-inflammatory cytokines TNF α and IFN γ , fibroblasts reduce lymphocyte migration in an IL-6 dependent fashion; these effects are not seen in the absence of TNF α /IFN γ (31), suggesting that healthy fibroblasts play an immunomodulatory role by preventing inappropriate recruitment of leukocytes to areas of acute inflammation. This is in contrast to the pathogenic role that fibroblasts play in chronic inflammation

2.4 The recruitment postcode

The specific combination of receptors, chemokines and other agents driving leukocyte transmigration is often referred to as the recruitment postcode (2). When fibroblasts and ECs are co-cultured, alterations in genotype are observed in both cells. These changes are dependent on the anatomical source of the fibroblasts (32). The phenotype of the fibroblast itself however, is also altered by inflammatory stimuli (8, 33). It is therefore probable that the fibroblast, rather than the endothelial cell is the primary protagonist in modulating tissue-specific, stimulus-specific inflammatory responses through control of endothelial cell function.

2.5 Fibroblast activation

Fibroblast activation refers to the process by which fibroblasts rapidly produce cytokines, chemokines, prostanoids, large amounts of ECM proteins (both constituents and degradation proteins) and express α -smooth-muscle actin in response to tissue injury (7, 17, 34). Activated fibroblasts are found in damaged, inflamed or healing tissue. These activated cells regulate the behaviour of leukocytes that are recruited to damaged tissue. CD40-CD40 ligand interactions is known to regulate this process by activating the nuclear factor (NF)- κ B family of transcription factors, leading to myofibroblast production of large amounts of IL-6, IL-8, cyclooxygenase-2 (COX-2) and hyaluronan

(35, 36). Cytokines and chemokines produced by fibroblasts appear to be specific to the type of injurious stimulus and the anatomical site of pathology (15).

3.0 The stroma in chronic inflammation

Chronic inflammation is characterised by its persistence, predilection for certain anatomical sites and propensity to be associated with significant disease related comorbidity including cancer, infection and diseases affecting the cardiovascular system and bone. Inflammation can only resolve if leukocyte recruitment, accumulation and survival is outweighed by leukocyte emigration and apoptosis at the site of inflammation. Why chronic inflammation fails to completely resolve, even after removal of injurious stimuli has, until relatively recently been poorly understood.

3.1 Accumulation of epigenetic changes and stability of the inflamed microenvironment

The structural composition of inflammatory sites at a microscopic level shows that the tissue microenvironment is defined largely by resident stromal cells such as fibroblasts (17). In chronic inflammation and during tissue fibrosis, fibroblasts maintain a state of permanent activation even once the initial stimulus has regressed. This activated phenotype persists until cells reach senescence (7). As with alterations in fibroblast phenotype by anatomical site, activated fibroblasts from diseased tissue (kidney, synovium, lung parenchyma) are also distinct in their phenotype and immune properties compared to fibroblasts from the same site in health (37-39). Furthermore, persistent activation of fibroblasts is stable; they maintain their distinctive phenotype even in tissue culture and in the absence of external stimulation and leukocytes (17). These findings indicate that permanently activated fibroblasts create inflamed tissue microenvironments that are intrinsically imprinted and stable (17). The molecular basis of persistent fibroblast activation in chronic inflammation is poorly understood. However recent evidence suggests that stable epigenetic modifications of the fibroblast genome (e.g. DNA hypomethylation) in response to inflammatory insults may be an important contributing factor (40, 41). Repeated episodes of acute, non-resolving inflammation may cause multiple epigenetic changes in the genome of the fibroblast, having a synergistic effect on promotion of stability of the activated, site-specific phenotype.

3.2 Recruitment of leukocytes to sites of chronic inflammation

Evidence from co-culture models suggests that physiological stromal tissue, which is not imprinted with an inflammatory phenotype, can become immunomodulatory, inhibiting and regulating leukocyte migration through ECs via IL-6 cytokine signalling (31). In contrast to fibroblasts from healthy tissue, rheumatoid arthritis synovial fibroblasts (RA-SFs) activate co-cultured ECs and support recruitment and migration of neutrophils and lymphocytes *in vitro* in the absence of external stimuli (32, 42-44). Adhesion of infiltrating leukocytes to stromal tissue appears to be mediated by fibroblast-derived chemokines (42). Neutrophil activation occurs when CXCR2 binds CXCL5, lymphocyte activation occurs when CXCR4 binds to CXCL12, also known as stromal derived factor-1 (SDF-1) (32, 42, 43). For both lymphocytes and neutrophils, recruitment is dependent on IL-6 generated in the co-culture period (32, 42, 43).

Along with stimulation of adhesion and leukocyte activation, inflammatory fibroblasts from the rheumatoid synovium have been shown to promote onward migration of T cells through the endothelial cell layer in co-culture models (44). When T cells are brought in close contact with RA-SFs that have been cultured with ECs, migration through cell layers occurs significantly more rapidly than when the same experiment is performed with dermal fibroblasts. This difference appears to be mediated by the increased production of CXCL12/SDF-1 by the RA-SFs (45).

3.3 Retention of lymphocytes

The process of generating an adaptive immune response requires well-coordinated and precise immune cell migration. Dendritic cells must sample antigen from the site of inflammation, then migrate to the draining lymph node to present the antigen to helper T cells. This process

requires specific, accurate and timely chemokine gradients to ensure that the immune cells interact at the right time, and in the right place. It has been suggested that activated fibroblasts may destabilise the physiological chemokine gradients underpinning this process through the upregulation and secretion of chemokines which promote retention of lymphocytes at a particular site. (47)

Leukocyte survival factors such as type 1 interferons, CXCR4 and its ligand CXCL12/SDF-1 contribute to the retention of lymphocytes as lymphoid aggregates in secondary lymphoid tissue (17, 57-59). SDF-1/CXCL12 is usually responsible for retention of lymphocytes within the bone marrow. Up-regulation of CXCR4 on infiltrating T lymphocytes by stromal derived TGF- β and expression of SDF-1 has been observed in inflamed synovium, intestine and skin (60, 61). It is also possible that fibroblasts imprinted with an inflammatory phenotype fail to switch off production of SDF-1 (17). These findings suggest that 'pro-retention' factors are important in the maintenance of the chronic inflammation; promoting retention of lymphocytes in an area of inflammation and inhibition of leukocyte migration minimises disruption. In other words the inflamed microenvironment becomes even more stable.

3.4 Tertiary lymphoid organs (TLOs)

The chemokines and adhesion molecules involved in recruitment of T cells to specific anatomical sites in health are well characterised. (46). Naïve T cells display a restricted pattern of recirculation, homing only to secondary lymphoid tissue using L-selectin, LFA-1 and the chemokine receptor CCR7. Memory T cells, in contrast, migrate to any anatomical site depending on the specific pattern of chemokines, receptors and adhesion molecules expressed (47).

As outlined above, activated fibroblasts undergo epigenetic and phenotypic changes in response to chronic inflammation. Activated rheumatoid synovial fibroblasts for example can resemble lymphoid fibroblasts when appropriately stimulated for long enough during episodes of acute inflammation (8, 33, 47, 48). When the stromal area postcode becomes sufficiently disordered in non-infectious/non-antigen specific chronic inflammation, fibroblasts and endothelial cells drive T-lymphocytes to accumulate at the area of disease and become organised into aggregates with structure reminiscent of lymph node structures, termed tertiary lymphoid organs (TLOs). (49).

TLOs are found in many chronic autoimmune disorders including rheumatoid arthritis, type 1 diabetes mellitus, Sjogren's syndrome, Hashimoto's thyroiditis and Crohn's disease (16). The mechanism for TLO formation has been explored in mouse models of diabetes where the expression of the homeostatic/lymphoid chemokine CXCL13 within pancreatic islets causes B cell recruitment and lymphoid neogenesis (50). CCL21, a chemokine specific to naïve lymphocytes, when ectopically expressed in transgenic mouse models, also leads to accumulation of T cell lymphoid infiltrates (51). More recent studies have shown that CXCL13 blockade disrupts B lymphocyte organization in tertiary lymphoid structures in non-obese diabetic mice (52). In the rheumatoid synovium, lymphoid-like fibroblasts produce CXCL13 and CCL19 driving lymphoid neogenesis (17, 45, 53). CCL19, VCAM-1 and ICAM-1 have been shown to play a role in TLO formation (54, 55).

Lymphoid-like fibroblasts also express Gp38 (podoplanin), a glycoprotein which is expressed by cells within areas of healthy, secondary lymphoid tissue (16). In non-lymphoid, physiological fibroblasts, gp38 is not expressed. Upon transformation of fibroblasts into a lymphoid like phenotype, gp38 and CD157 (BP-3) become expressed, leading to production of IL-7 and the lymphoid cytokines CXCL13 and CCL19 (17, 45, 53). Expression of gp38 has also been detected in various types of malignancy. In both malignancy and chronic inflammation, expression of gp38 corresponds with disease aggression and poor prognosis (16). Accordingly, it is important to note that the histological finding of TLOs in the synovium of patients with early RA is associated with severe disease progression and erosive disease (56).

3.5 Inhibition of leukocyte apoptosis

Resolution of an inflammatory response requires the removal of the majority of immune cells that were recruited and then proliferated at a site of inflammation. This process involves leukocyte emigration from the site of pathology and extensive apoptosis of activated T-cells (58). To maintain immunological memory, a few of these T cells must survive the wave of tissue apoptosis. The process of T-cell apoptosis at sites of pathology is therefore tightly regulated. There is now strong evidence that this process is stromal cell mediated (58).

In order to resolve an acute episode of inflammation, active Fas-induced apoptosis of leukocytes occurs, limiting the extent of tissue damage and acting as the trigger for the resolution phase (62). This process acts in synergy with apoptosis resulting from cytokine deprivation (63).

In T-cells, IL-2 (predominantly), IL-4, IL-7, IL-9 and IL-15 use a shared receptor signalling component which forms the γ chain of the IL-2 receptor (58, 64, 65). When these cytokines are withdrawn, T cell apoptosis occurs readily (66). This cytokine-mediated inhibition of apoptosis occurs via upregulation of the genes BCL-2 and Bcl-x_L and increased T-cell proliferation (64). Cytokine-deprived T cells in rheumatoid arthritis however may be rescued from apoptosis via interaction with RA-SFs (64, 67). This process however, does not involve increased expression of BCL-2 or T-cell proliferation (66), suggesting that fibroblast mediated inhibition of T-cell apoptosis occurs via a mechanism which is distinct from cytokine deprivation. The NF- κ B family of transcription factors which is heavily upregulated in the rheumatoid synovium has been implicated in the regulation of bcl-2 regulated apoptosis (68). Type one interferons, particularly IFN- β , are the predominant factors influencing stromal mediated inhibition of apoptosis (58). Our group has proposed therefore, that RA-SF mediated blockade of lymphocyte death through upregulation of aberrant 'pro-survival' cytokines/chemokines is a major contributing factor to the persistence of T cell infiltration despite low levels of T-cell cytokines in the chronically inflamed rheumatoid synovium (64).

B-cell survival depends on fibroblast production of IL-6 and expression of CXCL12 (69). Expression of the type II membrane proteins; BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) by RA-SFs have been shown to mediate B cell survival and function within the RA synovium (70).

3.6 Tissue destruction in RA

RA-synovial fibroblasts (RA-SFs) within the lining layer of the synovial joint cartilage are known to contribute to joint destruction and bony erosions through expression of degradation enzymes such as MMPs (71). MMP-2, MMP-9 and MMP-13 have been specifically implicated (72). MMP-9 is also upregulated by CXCL12 (SDF-1) (73). Fibroblast activation protein (FAP) is expressed at high levels in the lining layer of the synovium, and is co-localised with MMP-13 within the rheumatoid synovium (74). Cathepsins, a major group of proteases, which are involved in joint destruction, have also been shown to be upregulated in the rheumatoid synovium (75). When RA-SFs are transfected with the *ras* proto-oncogene, cathepsin L is upregulated (76). The pro-inflammatory cytokines IL-1, IL-6 and TNF α also stimulate the production of cathepsins; an effect mediated by RA-SFs (77).

3.7 p21 cyclin dependent kinase inhibitors (CDKi)

Cyclin dependent kinases (CDKs) are primarily responsible for regulation of the cell cycle. CDKi overexpression induces cell cycle arrest (78). p21, a CDKi has been shown to inhibit arthritis development in mouse models (79). The expression of p21 by synovial fibroblasts is reduced in isolated RA-SFs compared to OA synovial fibroblasts (80). In p21-deficient synovial fibroblasts in mice, a 100-fold increase in IL-6 protein and enhanced IL-6 mRNA is seen (80). Overexpression of MMPs and cathepsins has also been noted in p21 deficient mice (81) thus suggesting a protective, anti-inflammatory role for p21 CDKi in RA.

Table 2: Fibroblast mediated persistence of chronic inflammation

Recruitment	TLO formation	Retention	Reduced emigration	Reduced apoptosis
IL-1	gp38	IFN-1	CXCL12 (SDF-1)	Bcl-x _L
IL-6	CD157 (BP-3)	IL-15	CCL21	BCI-2*
TNF α	IL-7	BAFF		IFN- β
COX-2	CXCL13 (BLC)	CXCL12 (SDF-1)		NF- κ B
CXCL8/IL-8	CCL19	CXCR4		IL-2
CCL5	CCL21 (SLC)	TGF- β		IL-4
CXCL1	ICAM-1			IL-15
CXCR2	VCAM-1			BAFF [^]
CXCL5				APRIL [^]
CXCL12 (SDF-1)				IL-6 [^]
				CXCL12 [^] (SDF-1)

*Low levels of BCL-2 are observed during fibroblast mediated inhibition of lymphocyte apoptosis. All other molecules are up regulated by fibroblasts to modulate persisting inflammation. [^]Increase survival of B-cells.

3.8 The synovium in patients with early rheumatoid arthritis

The model of persistent inflammation in RA proposed above requires the presence of lymphoid aggregates and a hyperplastic synovium. These features are rare in patients with active synovitis in the early stages of the disease. It is therefore likely that the pathological mechanisms underpinning disease initiation are distinct from those causing disease persistence. Additionally the observation that spontaneous remission is unusual when an inflammatory arthritis has persisted for longer than 6 months (82) suggests that the stromal-mediated processes, as outlined above, are well established by this time. In support of this idea is the finding that the cytokine/chemokine profile in the synovial fluid of patients with early (less than 12 weeks onset) synovitis who were likely to subsequently progress to persistent RA was distinct from synovial fluid from the same patient cohort who were unlikely to progress to established RA (83). The early synovial cytokine/chemokine profile from patients who were likely to develop RA demonstrated high levels of T-cell, macrophage and stromal derived cytokines (IL-2, IL-4, IL-13, IL-17, IL-1, IL-15, bFGF and EGF). This profile is transient and is not present in the synovium of patients with persistent disease. These findings suggest that the type of immune response that leads to RA involves stromal components and Th2 cytokines and is likely to influence the biology of the tissue microenvironment required for persistent disease (83).

4.0 Biological agents in RA that target the stroma

Cytokine inhibition using biological therapies has revolutionized the management of rheumatoid arthritis in recent years. Despite the successes of this approach, we are still unable to cure the disease. Most therapies share a maximum therapeutic response rate of around 20% achieving an ACR 70 response (15). As we have outlined, stromal derived cytokines such as IL-1, IL-6 and TNF α are intermediate effectors of the autoimmune response in RA. It is therefore not surprising that their blockade dampens inflammation as opposed to eliminating it. In this review we have outlined that stromal elements, in particular fibroblasts, act upstream of these cytokines and are

responsible for the persistence of chronic inflammation in rheumatoid arthritis. There are however, at present, no therapeutic agents available which directly target the fibroblasts, nor are there agents which target the potent fibroblast-effectors modulating persistence (TLO formation, pro-retention factors and pro-survival factors). However, conventional biologics do have effects on the stroma and their cellular products. For example Tocilizumab, which targets IL-6, has anti stromal effects. In active rheumatoid arthritis, IL-6 is found in abundance in both the synovium and the circulation (32). Within the inflamed synovium, IL-6 is produced by activated synovial fibroblasts and is pro-inflammatory. Downstream pro-inflammatory effects include stimulation of differentiation of B cells into immunoglobulin secreting plasma cells, activation of T cells (84), promotion of B-cell survival (69), and the recruitment of neutrophils and lymphocytes (32, 42, 43). IL-6 also contributes to joint destruction by interaction with cathepsins (77).

4.1 Possible future stromal targets

Cellular MAPK and NF- κ B pathways are heavily implicated in the inhibition of T cell apoptosis in the rheumatoid synovium. These pathways however are generic; involved in directing the cellular responses in numerous cellular systems. More specific MAPK effectors are therefore being targeted, of which p38 MAPKs which share similarities with the janus kinase pathway are known to impact on synovial fibroblast biology (86).

Fibroblasts express a number of sensitive, but non-specific markers (Table 1). Targeting pathogenic fibroblasts alone, without collateral damage, is therefore a challenge. Research is currently underway to identify pathogenic fibroblast markers. Cadherin-11 is both a sensitive fibroblast marker and is relatively specific to the inflammatory synovium in mouse models of arthritis. Cadherin-11 promotes invasive behaviour of RA-SFs (87). Its high specificity to pathological states makes it an attractive potential target for further investigation. CD248 is a similar fibroblast target, which has a role in adhesion and its blockade in mouse models of arthritis has been promising (88). RA-SFs express low levels of the p21 CDKi, translating to a pro-inflammatory effect mediated by IL-6 (80). Adenovirus mediated p21 gene transfer to RA-SFs is currently under investigation to treat RA in early clinical trials. Finally, blockade of CXCR4, the receptor for CXCL12/SDF-1 using the antagonist AMD3100 in mouse models of arthritis has shown significant reduction in disease severity (89) In human trials however, its use has been abandoned due to its adverse effects including bone marrow suppression (15).

5.0 Conclusions

Fibroblasts play a role in regulating the accumulation of leucocytes in inflamed tissues. In response to recurrent inflammatory stimuli, fibroblasts undergo phenotypic alterations, which alter their pathogenic potential. These alterations are very specific and contextual. In the case of inflammatory states such as rheumatoid arthritis, the fibroblast phenotype changes to one which behaves like a lymphoid fibroblast; supporting leukocyte adhesion and migration, lymphoid neogenesis, retention of leukocytes and inhibition of leukocyte apoptosis. All of these promote persistent and stable inflammation within the synovium.

Currently available biologic agents for use in rheumatoid arthritis do not directly target the fibroblast but do target their cell products (eg IL-6), which mediate persistence of inflammation. As such, current available therapies for rheumatoid arthritis do not truly target the persistence of inflammation. Novel therapeutic agents directed at tissue resident stromal cells and which aid their depletion offers an exciting new avenue of research. These agents may turn out to be the key to the cure of persistent inflammatory disorders such as rheumatoid arthritis.

6.0 Practice points

- IL-1, IL-6 and TNF α blockade is useful to suppress persistent disease activity in patients with rheumatoid arthritis
- Future targeting of stromal pathways involved in the switch of acute to chronic inflammation (gp38, CXCR4) may be useful to prevent persistent synovitis and joint destruction in patients with early (<12 weeks) synovitis

7.0 Research Agenda

- Continued search for more specific fibroblast markers
- Data on the use of novel fibroblast targeted agents/genetic therapies for use in chronic inflammatory conditions
- Targeting epigenetic modifications to alter RA-SF phenotype
- Development of a unified understanding of the immunopathogenesis of rheumatoid arthritis, with particular focus on the immune mechanisms underpinning the switch from resolving to persistent inflammation to guide research into more novel targets that may be used to prevent rheumatoid arthritis in patients with early synovitis who are at significant risk of developing persistent disease.

References

1. Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, O'Neill LA, et al. Resolution of inflammation: state of the art, definitions and terms. *FASEB J*. 2007 Feb;21(2):325-32.
2. McGettrick HM, Butler LM, Buckley CD, Rainger GE, Nash GB. Tissue stroma as a regulator of leukocyte recruitment in inflammation. *J Leukoc Biol*. 2012 Mar;91(3):385-400.
3. Tailor A, Flower RJ, Perretti M. Dexamethasone inhibits leukocyte emigration in rat mesenteric post-capillary venules: an intravital microscopy study. *J Leukoc Biol*. 1997 Sep;62(3):301-8.
4. Filer A, Raza K, Salmon M, Buckley CD. Targeting stromal cells in chronic inflammation. *Discov Med*. 2007 Feb;7(37):20-6.
5. Phan SH. Biology of fibroblasts and myofibroblasts. *Proc Am Thorac Soc*. 2008 Apr 15;5(3):334-7.
6. Buckley CD, Halder S, Hardie D, Reynolds G, Torensma R, De Villeroche VJ, et al. Report on antibodies submitted to the stromal cell section of HLD48. *Cell Immunol*. 2005 Jul-Aug;236(1-2):29-41.
7. Kalluri R, Zeisberg M. Fibroblasts in cancer. *Nat Rev Cancer*. 2006 May;6(5):392-401.
8. Chang HY, Chi JT, Dudoit S, Bondre C, van de Rijn M, Botstein D, et al. Diversity, topographic differentiation, and positional memory in human fibroblasts. *Proc Natl Acad Sci U S A*. 2002 Oct 1;99(20):12877-82.
9. Hematti P. Mesenchymal stromal cells and fibroblasts: a case of mistaken identity? *Cytotherapy*. 2012 May;14(5):516-21.
10. Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. *Cell Stem Cell*. 2013 Oct 3;13(4):392-402.
11. Komuro T. Re-evaluation of fibroblasts and fibroblast-like cells. *Anat Embryol (Berl)*. 1990;182(2):103-12.
12. Rodemann HP, Muller GA. Characterization of human renal fibroblasts in health and disease: II. In vitro growth, differentiation, and collagen synthesis of fibroblasts from kidneys with interstitial fibrosis. *Am J Kidney Dis*. 1991 Jun;17(6):684-6.
13. Simian M, Hirai Y, Navre M, Werb Z, Lochter A, Bissell MJ. The interplay of matrix metalloproteinases, morphogens and growth factors is necessary for branching of mammary epithelial cells. *Development*. 2001 Aug;128(16):3117-31.
14. Naylor AJ, Filer A, Buckley CD. The role of stromal cells in the persistence of chronic inflammation. *Clin Exp Immunol*. 2013 Jan;171(1):30-5.
15. Filer A. The fibroblast as a therapeutic target in rheumatoid arthritis. *Curr Opin Pharmacol*. 2013 Jun;13(3):413-9.
16. Barone F, Nayar S, Buckley CD. The role of non-hematopoietic stromal cells in the persistence of inflammation. *Front Immunol*. 2012;3:416.
17. Buckley CD, Pilling D, Lord JM, Akbar AN, Scheel-Toellner D, Salmon M. Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation. *Trends Immunol*. 2001 Apr;22(4):199-204.
18. Wiseman BS, Werb Z. Stromal effects on mammary gland development and breast cancer. *Science*. 2002 May 10;296(5570):1046-9.
19. Rettig WJ, Su SL, Fortunato SR, Scanlan MJ, Raj BK, Garin-Chesa P, et al. Fibroblast activation protein: purification, epitope mapping and induction by growth factors. *Int J Cancer*. 1994 Aug 1;58(3):385-92.
20. Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. *Science*. 2010 Nov 5;330(6005):827-30.
21. Dolberg DS, Hollingsworth R, Hertle M, Bissell MJ. Wounding and its role in RSV-mediated tumor formation. *Science*. 1985 Nov 8;230(4726):676-8.
22. Brown LF, Guidi AJ, Schnitt SJ, Van De Water L, Iruela-Arispe ML, Yeo TK, et al. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. *Clin Cancer Res*. 1999 May;5(5):1041-56.
23. McEver RP. Selectins: lectins that initiate cell adhesion under flow. *Curr Opin Cell Biol*. 2002 Oct;14(5):581-6.

24. Pober JS, Cotran RS. Cytokines and endothelial cell biology. *Physiol Rev.* 1990 Apr;70(2):427-51.
25. Springer TA. Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. *Annu Rev Physiol.* 1995;57:827-72.
26. Luscinskas FW, Ding H, Lichtman AH. P-selectin and vascular cell adhesion molecule 1 mediate rolling and arrest, respectively, of CD4+ T lymphocytes on tumor necrosis factor alpha-activated vascular endothelium under flow. *J Exp Med.* 1995 Mar 1;181(3):1179-86.
27. Piali L, Weber C, LaRosa G, Mackay CR, Springer TA, Clark-Lewis I, et al. The chemokine receptor CXCR3 mediates rapid and shear-resistant adhesion-induction of effector T lymphocytes by the chemokines IP10 and Mig. *Eur J Immunol.* 1998 Mar;28(3):961-72.
28. Luu NT, Rainger GE, Nash GB. Differential ability of exogenous chemotactic agents to disrupt transendothelial migration of flowing neutrophils. *J Immunol.* 2000 Jun 1;164(11):5961-9.
29. Sheikh S, Rahman M, Gale Z, Luu NT, Stone PC, Matharu NM, et al. Differing mechanisms of leukocyte recruitment and sensitivity to conditioning by shear stress for endothelial cells treated with tumour necrosis factor-alpha or interleukin-1beta. *Br J Pharmacol.* 2005 Aug;145(8):1052-61.
30. Dangerfield JP, Wang S, Nourshargh S. Blockade of alpha6 integrin inhibits IL-1beta- but not TNF-alpha-induced neutrophil transmigration in vivo. *J Leukoc Biol.* 2005 Feb;77(2):159-65.
31. McGettrick HM, Hunter K, Moss PA, Buckley CD, Rainger GE, Nash GB. Direct observations of the kinetics of migrating T cells suggest active retention by endothelial cells with continual bidirectional migration. *J Leukoc Biol.* 2009 Jan;85(1):98-107.
32. McGettrick HM, Smith E, Filer A, Kissane S, Salmon M, Buckley CD, et al. Fibroblasts from different sites may promote or inhibit recruitment of flowing lymphocytes by endothelial cells. *Eur J Immunol.* 2009 Jan;39(1):113-25.
33. Filer A, Parsonage G, Smith E, Osborne C, Thomas AM, Curnow SJ, et al. Differential survival of leukocyte subsets mediated by synovial, bone marrow, and skin fibroblasts: site-specific versus activation-dependent survival of T cells and neutrophils. *Arthritis Rheum.* 2006 Jul;54(7):2096-108.
34. Zeisberg M, Strutz F, Muller GA. Role of fibroblast activation in inducing interstitial fibrosis. *J Nephrol.* 2000 Nov-Dec;13 Suppl 3:S111-20.
35. Smith RS, Smith TJ, Blieden TM, Phipps RP. Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation. *Am J Pathol.* 1997 Aug;151(2):317-22.
36. Zhang Y, Cao HJ, Graf B, Meekins H, Smith TJ, Phipps RP. CD40 engagement up-regulates cyclooxygenase-2 expression and prostaglandin E2 production in human lung fibroblasts. *J Immunol.* 1998 Feb 1;160(3):1053-7.
37. Hogaboam CM, Steinhauser ML, Chensue SW, Kunkel SL. Novel roles for chemokines and fibroblasts in interstitial fibrosis. *Kidney Int.* 1998 Dec;54(6):2152-9.
38. Pap T, Muller-Ladner U, Gay RE, Gay S. Fibroblast biology. Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. *Arthritis Res.* 2000;2(5):361-7.
39. Hogaboam CM, Bone-Larson CL, Lipinski S, Lukacs NW, Chensue SW, Strieter RM, et al. Differential monocyte chemoattractant protein-1 and chemokine receptor 2 expression by murine lung fibroblasts derived from Th1- and Th2-type pulmonary granuloma models. *J Immunol.* 1999 Aug 15;163(4):2193-201.
40. Karouzakis E, Gay RE, Michel BA, Gay S, Neidhart M. DNA hypomethylation in rheumatoid arthritis synovial fibroblasts. *Arthritis Rheum.* 2009 Dec;60(12):3613-22.
41. Ospelt C, Reedquist KA, Gay S, Tak PP. Inflammatory memories: is epigenetics the missing link to persistent stromal cell activation in rheumatoid arthritis? *Autoimmun Rev.* 2011 Jul;10(9):519-24.
42. Smith E, McGettrick HM, Stone MA, Shaw JS, Middleton J, Nash GB, et al. Duffy antigen receptor for chemokines and CXCL5 are essential for the recruitment of neutrophils in a multicellular model of rheumatoid arthritis synovium. *Arthritis Rheum.* 2008 Jul;58(7):1968-73.
43. Lally F, Smith E, Filer A, Stone MA, Shaw JS, Nash GB, et al. A novel mechanism of neutrophil recruitment in a coculture model of the rheumatoid synovium. *Arthritis Rheum.* 2005 Nov;52(11):3460-9.
44. McGettrick HM, Buckley CD, Filer A, Rainger GE, Nash GB. Stromal cells differentially regulate neutrophil and lymphocyte recruitment through the endothelium. *Immunology.* 2010 Nov;131(3):357-70.
45. Bradfield PF, Amft N, Vernon-Wilson E, Exley AE, Parsonage G, Rainger GE, et al. Rheumatoid fibroblast-like synoviocytes overexpress the chemokine stromal cell-derived factor 1 (CXCL12), which

supports distinct patterns and rates of CD4+ and CD8+ T cell migration within synovial tissue. *Arthritis Rheum.* 2003 Sep;48(9):2472-82.

46. Campbell JJ, Haraldsen G, Pan J, Rottman J, Qin S, Ponath P, et al. The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. *Nature.* 1999 Aug 19;400(6746):776-80.
47. Burman A, Haworth O, Hardie DL, Amft EN, Siewert C, Jackson DG, et al. A chemokine-dependent stromal induction mechanism for aberrant lymphocyte accumulation and compromised lymphatic return in rheumatoid arthritis. *J Immunol.* 2005 Feb 1;174(3):1693-700.
48. Fries KM, Blieden T, Looney RJ, Sempowski GD, Silvera MR, Willis RA, et al. Evidence of fibroblast heterogeneity and the role of fibroblast subpopulations in fibrosis. *Clin Immunol Immunopathol.* 1994 Sep;72(3):283-92.
49. Nishikawa SI, Hashi H, Honda K, Fraser S, Yoshida H. Inflammation, a prototype for organogenesis of the lymphopoietic/hematopoietic system. *Curr Opin Immunol.* 2000 Jun;12(3):342-5.
50. Luther SA, Lopez T, Bai W, Hanahan D, Cyster JG. BLC expression in pancreatic islets causes B cell recruitment and lymphotoxin-dependent lymphoid neogenesis. *Immunity.* 2000 May;12(5):471-81.
51. Fan L, Reilly CR, Luo Y, Dorf ME, Lo D. Cutting edge: ectopic expression of the chemokine TCA4/SLC is sufficient to trigger lymphoid neogenesis. *J Immunol.* 2000 Apr 15;164(8):3955-9.
52. Henry RA, Kendall PL. CXCL13 blockade disrupts B lymphocyte organization in tertiary lymphoid structures without altering B cell receptor bias or preventing diabetes in nonobese diabetic mice. *J Immunol.* 2010 Aug 1;185(3):1460-5.
53. Peduto L, Dulauroy S, Lochner M, Spath GF, Morales MA, Cumano A, et al. Inflammation recapitulates the ontogeny of lymphoid stromal cells. *J Immunol.* 2009 May 1;182(9):5789-99.
54. Manzo A, Paoletti S, Carulli M, Blades MC, Barone F, Yanni G, et al. Systematic microanatomical analysis of CXCL13 and CCL21 in situ production and progressive lymphoid organization in rheumatoid synovitis. *Eur J Immunol.* 2005 May;35(5):1347-59.
55. Hjelmstrom P. Lymphoid neogenesis: de novo formation of lymphoid tissue in chronic inflammation through expression of homing chemokines. *J Leukoc Biol.* 2001 Mar;69(3):331-9.
56. van de Sande MG, Thurlings RM, Boumans MJ, Wijbrandts CA, Modesti MG, Gerlag DM, et al. Presence of lymphocyte aggregates in the synovium of patients with early arthritis in relationship to diagnosis and outcome: is it a constant feature over time? *Ann Rheum Dis.* 2011 Apr;70(4):700-3.
57. Pilling D, Fan T, Huang D, Kaul B, Gomer RH. Identification of markers that distinguish monocyte-derived fibrocytes from monocytes, macrophages, and fibroblasts. *PLoS One.* 2009;4(10):e7475.
58. Pilling D, Akbar AN, Girdlestone J, Orteu CH, Borthwick NJ, Amft N, et al. Interferon-beta mediates stromal cell rescue of T cells from apoptosis. *Eur J Immunol.* 1999 Mar;29(3):1041-50.
59. Parsonage G, Falciani F, Burman A, Filer A, Ross E, Bofill M, et al. Global gene expression profiles in fibroblasts from synovial, skin and lymphoid tissue reveals distinct cytokine and chemokine expression patterns. *Thromb Haemost.* 2003 Oct;90(4):688-97.
60. Pablos JL, Amara A, Boulloc A, Santiago B, Caruz A, Galindo M, et al. Stromal-cell derived factor is expressed by dendritic cells and endothelium in human skin. *Am J Pathol.* 1999 Nov;155(5):1577-86.
61. Agace WW, Amara A, Roberts AI, Pablos JL, Thelen S, Uguccioni M, et al. Constitutive expression of stromal derived factor-1 by mucosal epithelia and its role in HIV transmission and propagation. *Curr Biol.* 2000 Mar 23;10(6):325-8.
62. Nagata S, Golstein P. The Fas death factor. *Science.* 1995 Mar 10;267(5203):1449-56.
63. Orteu CH, Poulter LW, Rustin MH, Sabin CA, Salmon M, Akbar AN. The role of apoptosis in the resolution of T cell-mediated cutaneous inflammation. *J Immunol.* 1998 Aug 15;161(4):1619-29.
64. Salmon M, Scheel-Toellner D, Huissoon AP, Pilling D, Shamsadeen N, Hyde H, et al. Inhibition of T cell apoptosis in the rheumatoid synovium. *J Clin Invest.* 1997 Feb 1;99(3):439-46.
65. Orteu CH, Rustin MH, O'Toole E, Sabin C, Salmon M, Poulter LW, et al. The inhibition of cutaneous T cell apoptosis may prevent resolution of inflammation in atopic eczema. *Clin Exp Immunol.* 2000 Nov;122(2):150-6.
66. Akbar AN, Borthwick NJ, Wickremasinghe RG, Panayiotidis P, Pilling D, Bofill M, et al. Interleukin-2 receptor common gamma-chain signaling cytokines regulate activated T cell apoptosis in

response to growth factor withdrawal: selective induction of anti-apoptotic (bcl-2, bcl-xL) but not pro-apoptotic (bax, bcl-xS) gene expression. *Eur J Immunol.* 1996 Feb;26(2):294-9.

67. Akbar AN, Borthwick N, Salmon M, Gombert W, Bofill M, Shamsadeen N, et al. The significance of low bcl-2 expression by CD45RO T cells in normal individuals and patients with acute viral infections. The role of apoptosis in T cell memory. *J Exp Med.* 1993 Aug 1;178(2):427-38.
68. Okamoto H, Hoshi D, Kiire A, Yamanaka H, Kamatani N. Molecular targets of rheumatoid arthritis. *Inflamm Allergy Drug Targets.* 2008 Mar;7(1):53-66.
69. Burger JA, Zvaifler NJ, Tsukada N, Firestein GS, Kipps TJ. Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a stromal cell-derived factor-1- and CD106 (VCAM-1)-dependent mechanism. *J Clin Invest.* 2001 Feb;107(3):305-15.
70. Bombardieri M, Kam NW, Brentano F, Choi K, Filer A, Kyburz D, et al. A BAFF/APRIL-dependent TLR3-stimulated pathway enhances the capacity of rheumatoid synovial fibroblasts to induce AID expression and Ig class-switching in B cells. *Ann Rheum Dis.* 2011 Oct;70(10):1857-65.
71. Clark IM, Powell LK, Ramsey S, Hazleman BL, Cawston TE. The measurement of collagenase, tissue inhibitor of metalloproteinases (TIMP), and collagenase-TIMP complex in synovial fluids from patients with osteoarthritis and rheumatoid arthritis. *Arthritis Rheum.* 1993 Mar;36(3):372-9.
72. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. *Nature.* 1994 Jul 7;370(6484):61-5.
73. Grassi F, Cristino S, Toneguzzi S, Piacentini A, Facchini A, Lisignoli G. CXCL12 chemokine up-regulates bone resorption and MMP-9 release by human osteoclasts: CXCL12 levels are increased in synovial and bone tissue of rheumatoid arthritis patients. *J Cell Physiol.* 2004 May;199(2):244-51.
74. Bauer S, Jendro MC, Wadle A, Kleber S, Stenner F, Dinser R, et al. Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes. *Arthritis Res Ther.* 2006;8(6):R171.
75. Huet G, Flipo RM, Richet C, Thiebaut C, Demeyer D, Balduyck M, et al. Measurement of elastase and cysteine proteinases in synovial fluid of patients with rheumatoid arthritis, sero-negative spondylarthropathies, and osteoarthritis. *Clin Chem.* 1992 Sep;38(9):1694-7.
76. Trabandt A, Aicher WK, Gay RE, Sukhatme VP, Nilson-Hamilton M, Hamilton RT, et al. Expression of the collagenolytic and Ras-induced cysteine proteinase cathepsin L and proliferation-associated oncogenes in synovial cells of MRL/l mice and patients with rheumatoid arthritis. *Matrix.* 1990 Dec;10(6):349-61.
77. Lemaire R, Huet G, Zerimech F, Grard G, Fontaine C, Duquesnoy B, et al. Selective induction of the secretion of cathepsins B and L by cytokines in synovial fibroblast-like cells. *Br J Rheumatol.* 1997 Jul;36(7):735-43.
78. Gao CY, Zelenka PS. Cyclins, cyclin-dependent kinases and differentiation. *Bioessays.* 1997 Apr;19(4):307-15.
79. Nasu K, Kohsaka H, Nonomura Y, Terada Y, Ito H, Hirokawa K, et al. Adenoviral transfer of cyclin-dependent kinase inhibitor genes suppresses collagen-induced arthritis in mice. *J Immunol.* 2000 Dec 15;165(12):7246-52.
80. Perlman H, Bradley K, Liu H, Cole S, Shamiyeh E, Smith RC, et al. IL-6 and matrix metalloproteinase-1 are regulated by the cyclin-dependent kinase inhibitor p21 in synovial fibroblasts. *J Immunol.* 2003 Jan 15;170(2):838-45.
81. Nonomura Y, Kohsaka H, Nagasaka K, Miyasaka N. Gene transfer of a cell cycle modulator exerts anti-inflammatory effects in the treatment of arthritis. *J Immunol.* 2003 Nov 1;171(9):4913-9.
82. Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. *Arthritis Rheum.* 2002 Feb;46(2):357-65.
83. Raza K, Falciani F, Curnow SJ, Ross EJ, Lee CY, Akbar AN, et al. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. *Arthritis Res Ther.* 2005;7(4):R784-95.
84. Muraguchi A, Hirano T, Tang B, Matsuda T, Horii Y, Nakajima K, et al. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. *J Exp Med.* 1988 Feb 1;167(2):332-44.
85. Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis: a Cochrane systematic review. *J Rheumatol.* 2011 Jan;38(1):10-20.

86. Rosengren S, Corr M, Firestein GS, Boyle DL. The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon. *Ann Rheum Dis*. 2012 Mar;71(3):440-7.
87. Kiener HP, Niederreiter B, Lee DM, Jimenez-Boj E, Smolen JS, Brenner MB. Cadherin 11 promotes invasive behavior of fibroblast-like synoviocytes. *Arthritis Rheum*. 2009 May;60(5):1305-10.
88. Maia M, de Vriese A, Janssens T, Moons M, van Landuyt K, Tavernier J, et al. CD248 and its cytoplasmic domain: a therapeutic target for arthritis. *Arthritis Rheum*. 2010 Dec;62(12):3595-606.
89. Matthys P, Hatse S, Vermeire K, Wuyts A, Bridger G, Henson GW, et al. AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice. *J Immunol*. 2001 Oct 15;167(8):4686-92.